Background Lifestyle interventions are recommended as first-line treatment in polyendocrine metabolic ovarian syndrome (PMOS), but their effectiveness across various outcomes remains unclear. In this systematic review, we evaluate the effectiveness of lifestyle interventions on reproductive, anthropometric, and metabol...
WLDPs appear to support individual development, but current evidence cannot establish organisational transformation, and their broader equity potential depends on structural accountability.
D. Morris, Sana Rauf, Kathleen Riach et al.· EClinicalMedicine· 1 citation
Recognizing PMOS as an early-life marker of cardiometabolic disease highlights opportunities for earlier diagnosis, prevention, and individualized risk stratification, supporting integrated, patient-centered care across the life course.
M. Forslund, J. Melin, A. Joham et al.· Journal of Internal Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.